Strongyloidiasis Treatment Outcomes: A Prospective Study Using Serological and Molecular Methods

Abstract

Strongyloidiasis, caused by the soil-transmitted helminth Strongyloides stercoralis, is estimated to infect around 600 million people worldwide. Ivermectin is the current first-line treatment. This prospective study evaluated long-term treatment response in patients with chronic strongyloidiasis. Conducted from 2019 to 2022 at Vega Baja Hospital in Alicante, Spain, this study enrolled 28 patients diagnosed with S. stercoralis infection. Patients received ivermectin at a dosage of 200 mcg/kg for one or two days and were followed for at least 12 months, with evaluations at 3, 6, 12, and 18 months post-treatment. Assessments included hemogram, IgE, Strongyloides serology, larvae culture and direct visualization and Strongyloides PCR in stool. Twenty-three patients completed at least 12 months of follow-up. Twenty-one patients (91.3%) achieved treatment response. Two patients (8.6%) experienced parasitological treatment failure, with detectable Strongyloides stercoralis DNA during follow-up. Ivermectin is highly effective in treating strongyloidiasis, with serology aiding in monitoring treatment efficacy. However, PCR detected an additional case of persistent infection, underscoring its complementary role.